HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes

Creative Commons License

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1111/jdi.13064


Title: Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
Authors: Miyoshi, Hideaki Browse this author →KAKEN DB
Kameda, Hiraku Browse this author
Yamashita, Kumiko Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Kurihara, Yoshio Browse this author
Keywords: Estimated glomerular filtration rate
Kidney disease
Sodium-glucose cotransporter 2 inhibitors inhibitor
Issue Date: Nov-2019
Publisher: John Wiley & Sons
Journal Title: Journal of diabetes investigation
Volume: 10
Issue: 6
Start Page: 1510
End Page: 1517
Publisher DOI: 10.1111/jdi.13064
Abstract: Aims/Introduction The risk of end-stage kidney disease increases in proportion to the decline in the estimated glomerular filtration rate (eGFR). Although protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the eGFR decline were shown in several large-scale clinical trials, there are no studies investigating patients with a high risk of end-stage kidney disease. We investigated the efficacy and safety of SGLT2i in advanced renal dysfunction patients (stage G3 or G4 of chronic kidney disease) with a rapid decline in eGFR. Materials and Methods This retrospective, longitudinal study enrolled patients with type 2 diabetes who were treated with SGLT2i, and whose eGFR was 20% over 2 years (%Delta eGFR-2y) before initiating SGLT2i. The primary end-point was the change in eGFR 2 years after initiation (%Delta eGFR+2y) compared with %Delta eGFR-2y. Results A total of 17 patients among 553 patients treated with SGLT2i for >= 2 years were included in the study. The average age, glycated hemoglobin and eGFR at SGLT2i initiation were 68.5 years, 7.3% and 38.3 mL/min/1.73 m(2), respectively. %Delta eGFR+2y in patients who were treated with SGLT2i was significantly increased compared with the patients not treated with SGLT2i (2.3 and -21.7%, respectively; P < 0.0001). A multiple regression analysis showed that only the proportion of the rate of eGFR decline was the independent factor associated with improvement of %Delta eGFR+2y. There was no increase in serious adverse events including acute kidney injury. Conclusions SGLT2i was safe, and prevented further eGFR decline in patients with type 2 diabetes and advanced renal dysfunction.
Rights: https://creativecommons.org/licenses/by-nc-nd/4.0/
Type: article
URI: http://hdl.handle.net/2115/76296
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University